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AbstrAct
Purpose: The complexity of sarcoma has led to the need for patient selection 
via in vivo biomarkers. Tumor endothelial marker-1 (TEM-1) is a cell surface marker 
expressed by the tumor microenvironment. Currently MORAb-004 (Ontuxizumab), an 
anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development 
of positron emission tomography (PET) for in vivo TEM-1 expression may allow 
for stratification of patients, potentially enhancing clinical outcomes seen with 
Ontuxizumab.
Results: Characterization of cell lines revealed clear differences in TEM-1 
expression. One high expressing (RD-ES) and one low expressing (LUPI) cell line 
were xenografted, and mice were injected with 89Zr-Ontuxizumab. PET imaging post-
injection revealed that TEM-1 was highly expressed and readily detectable in vivo only 
in RD-ES. In vivo biodistribution studies confirmed high radiopharmaceutical uptake 
in tumor relative to normal organs. 
Experimental Design: Sarcoma cell lines were characterized for TEM-1 
expression. Ontuxizumab was labeled with 89Zr and evaluated for immunoreactivity 
preservation. 89Zr-Ontuxizumab was injected into mice with high or null expressing 
TEM-1 xenografts. In vivo PET imaging experiments were performed. 
Conclusion: 89Zr-Ontuxizumab can be used in vivo to determine high versus low 
TEM-1 expression. Reliable PET imaging of TEM-1 in sarcoma patients may allow for 
identification of patients that will attain the greatest benefit from anti-TEM-1 therapy.
IntroductIon
The utility of biomarkers in the diagnosis, staging, 
and determination of clinical response to treatment is 
emerging as an invaluable tool in the care of cancer 
patients [1-4]. The use of a biomarker to not only image 
a malignancy, but to offer guidance as to which therapy 
would most benefit a patient is at the core of personalized 
therapy. The ability to delineate a patient’s clinical 
response to a biologic treatment would allow for patient 
stratification into groups that would either benefit from 
a treatment, or spare patients the costs and potential 
toxicities of ineffective treatments [5-7]. 
Tumor endothelial marker-1 (TEM-1), also referred 
to as endosialin or CD248, is a tumor vascular marker that 
is a 175k-Da type I transmembrane protein of the C-type 
lectin-like receptor family [5, 8-10]. It is most closely 
related to the family of transmembrane glycoproteins that 
includes thrombomodulin, functions in the angiogenesis 
process, and may also be involved in cell adhesion 
and migration. Its role in other cellular functions is not 
fully defined [6, 11-13]. TEM-1 is primarily expressed 
on tumor stroma and tumor vessels in multiple human 
cancers, but is not expressed in normal adult tissue or 
blood vessels [9, 10, 14-16]. A limited number of tumors 
have also been demonstrated to express TEM-1. By 
immunohistochemistry (IHC), the expression of TEM-
Oncotarget13083www.impactjournals.com/oncotarget
1 is restricted to stromal cells and tumor-associated 
perivascular cells in ovarian, breast, and lung cancers 
[17, 18]. In sarcoma, the expression of endosialin/
CD248/TEM-1 has been examined in cell culture, clinical 
specimens and animal models, and endosialin was found to 
be expressed frequently and at high levels in perivascular 
cells, stromal cells. The malignant cells themselves [17, 
19, 20]. A high level of endosialin expression on primary 
clinical samples of sarcoma suggests the potential utility 
of targeting endosialin/CD248/TEM-1 on sarcomas in vivo 
[17, 19, 20]. 
Previous work using a 124I-labled anti-TEM-1 
antibody illustrated the feasibility of using PET imaging 
to visualize this target in a cell line engineered to express 
high levels of TEM-1 [5]. Using 125I-labled Ontuxizumab 
TEM-1 positive tumor bearing mice were found to clear 
the antibody at a much slower rate that TEM-1 negative 
tumor bearing mice [5]. In addition, biodistribution studies 
demonstrated high uptake of iodinated Ontuxizumab in 
tumors compared to normal tissues [5]. The aims of the 
current study were twofold. First, to develop a 89Zr-PET 
imaging agent for imaging of TEM-1 expression as 89Zr 
is known to be a residualizing radionuclide (trapped 
inside cells after metabolism) and thus has the potential 
of generating higher quality images [21]. Secondly, we 
sought to examine the feasibility of imaging TEM-1 
expression on non-engineered sarcoma cell lines, in vivo, 
to assess the potential clinical utility of this agent.
At present, the ability to determine the clinical 
expression of TEM-1 in patients with metastatic disease 
relies on IHC of biopsies of single lesions or primary 
tumors that may not represent true TEM-1 expression 
when compared to the total tumor burden in a patient. 
Negative staining for TEM-1 may represent an artifact of 
processing or biopsy selection, while positive staining may 
only relate to the specific tumor that was biopsied and not 
the entire tumor burden. We proposed to develop a PET 
clinical screening test to determine which patients would 
most likely benefit from anti-TEM-1 therapy using 89Zr-
Ontuxizumab. 
results
teM-1 expression in sarcoma cell lines
To identify potential in vivo xenograft candidates, 
a panel of thirteen sarcoma cell lines was screened for 
Figure 1: teM-1 expression: High and null expressing sarcoma lines. A. FACS analysis using Ontuxizumab antibody and 
FITC-labeled anti-human secondary antibody to determine TEM1 expression. RD-ES (Ewing’s sarcoma) and FUJI (synovial sarcoma) 
show high TEM-1 expression. LUPI, a Ewing’s sarcoma line, and SYO-1, a synovial sarcoma line, display null to low expression of TEM-
1, respectively. b. Semi-quantitative immunofluorescence of TEM-1 expression. Cell lines RD-ES and FUJI display strong Ontuxizumab 
binding while LUPI and SYO-1 display null binding. Images were captured using an exposure time of 25 msec through a 60x objective 
keeping time constant across all images. c. NATIVE-PAGE Western blot showing high-expressing TEM-1 lines RD-ES and FUJI, with 
null-expressing lines LUPI and SYO-1. 
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TEM-1 expression by FACS. Three Ewing’s cell lines 
(SK-ES, RD-ES, and LUPI), three osteosarcoma cell lines 
(MG-63, MNNG-HOS, U2-OS) two synovial sarcoma 
cell lines (SYO-1, FUJI), two uterine sarcoma cell lines 
(SK-LMS-1, SK-UT), one fibrosarcoma (HT-1080), one 
rhabdomyosarcoma (RD), and one malignant peripheral 
nerve sheath tumor (MPNST) (ST-88-14) were assessed. 
Indirect FACS using Ontuxizumab and FITC-labeled anti-
human secondary antibody revealed that cell lines RD-
ES and FUJI displayed very high expression of TEM-1 
when compared to background (Figure 1A). Conversely, 
LUPI and SYO-1 were null and low expressers of TEM-1, 
respectively (Figure 1A). Binding of Ontuxizumab to these 
two paired cell lines was confirmed by semi-quantitative 
immunofluorescence; using fixed camera settings, the 
FITC-labeled anti-human antibody labeling of bound 
Ontuxizumab was noted to be positive in RD-ES and FUJI 
when compared to LUPI and SYO-1 (Figure 1B). Finally 
we performed NATIVE-PAGE Western blot analysis to 
confirm the expression of TEM-1 in RD-ES and FUJI 
when compared to LUPI and SYO-1 (Figure 1C); a rat 
monoclonal antibody to TEM-1 was used as Ontuxizumab 
only recognizes a three dimensional structure of TEM-1 
that is lost upon immunoblotting. FACS analysis 
(Supplemental Figure 1) and immunofluorescence 
(Supplemental Figure 2) of the remaining nine sarcoma 
cell lines revealed that both SK-ES, a Ewing’s sarcoma, 
and ST-88-14, a MPNST, displayed low to moderate 
TEM-1 expression, while the remainder of the panel were 
null expressers of TEM-1. 
dFo conjugation and 89Zr labeling does not affect 
binding or uptake of ontuxizumab
Ontuxizumab underwent chelator conjugation 
with 89Zr (Figure 2). To determine if 89Zr labeling of 
Ontuxizumab altered binding affinity, we performed 
binding and uptake assays. Cells were incubated with 
the radiolabeled antibody, lysed, and cell associated 
activity detected with a gamma-counter. Protein amount 
was measured with a BCA assay and the data expressed 
as counts per milligram of protein (CPM/mg protein). 
Binding of the radiolabeled antibody was significantly 
higher for RD-ES and FUJI when compared with LUPI 
and SYO-1 (Figure 3A). Immunoreactivity of the 
radiolabeled antibody was determined using 89Zr-Df-Bz-
NCS-Ab binding to immobilized TEM-1 in the presence 
of increasing amounts of Df-Bz-NCS-Ab (conjugated) or 
Ab (unconjugated). When assessing the binding affinity of 
unconjugated compared to conjugated antibody, there was 
no significant difference in CPM between conjugated and 
unconjugated antibody in vitro. Therefore, conjugation of 
the DFO and radiolabeling it with 89Zr did not change the 
antibody’s binding properties (Figure 3B). 
Another recently reported function of Ontuxizumab 
Figure 2: ontuxizumab conjugation. Ontuxizumab was conjugated to p-isothiocyanatobenzyl-desferrioxamine (DFO-Bz-NCS metal 
chelate) via lysine residues. After purification, the antibody conjugate was radiolabeled with 89Zr-oxalate under neutral pH conditions.
Oncotarget13085www.impactjournals.com/oncotarget
is internalization after binding to endosialin [28]. To 
determine if 89Zr altered the ability of Ontuxizumab to 
internalize after labeling we performed an in vitro uptake 
assay using the TEM-1 expressing cell line RD-ES (Figure 
3C). We found that the labeled antibody was internalized 
slowly, likely at the rate of receptor turnover, and that 
this was not saturable over 24 hours, thus suggesting 
that radioimmunotherapy or antibody conjugates using 
Ontuxizumab may be useful for drug development [29].
In vivo Pet imaging and biodistribution
One high expressing (RD-ES) and one null 
expressing (LUPI) cell line were xenografted with 1x106 
cells into nude athymic mice and observed for xenograft 
growth until tumor size reached 100 mm3. The mice 
were then anesthetized with isoflurane and treated with 
100 μCi (50 μg) 89Zr-labeled Ontuxizumab via tail vein 
injection. PET/CT imaging was performed on post-
injection days 3 and 7 and displayed as maximum intensity 
projections (MIP) of PET/CT images (Figure 4A). 89Zr-
labeled Ontuxizumab highly and reliably accumulated 
in vivo in RD-ES xenografts, while LUPI xenografts 
displayed lack of uptake (Figure 4A, middle and right 
panels, respectively). Background PET activity was not 
observed. Specificity of the 89Zr-labeled Ontuxizumab for 
the tumor was confirmed by blocking the radiolabeled 
antibody uptake with cold antibody administration 
(Figure 4A, left panel). Standard uptake values (SUV) 
were obtained from PET/CT images at post-injection day 
3 and day 7. Significant differences were noted in SUVs 
between blocked and non-blocked day 3 and day 7 RD-
ES xenografts (Figure 4B). The SUV from the day 3 and 
day 7 PET/CT image analyses of the RD-ES xenografts 
was significantly higher than that of the non-blocked day 
3 and day 7 SUVs for the LUPI xenografts (Figure 4B). In 
vivo biodistribution studies were performed 7 days post-
Figure 3: binding study and uptake. A. 89Zr-Df-Bz-NCS-Ab binding to selected sarcoma cell lines. Radiolabeled antibody was 
allowed to bind to selected cell lines for 35 min as described in the Methods section. RD-ES and FUJI cells demonstrated good binding 
of 89Zr-Df-Bz-NCS-Ab, while SYO-1 and LUPI showed no appreciable binding. b. Immunoreactivity of 89Zr-Df-Bz-NCS-Ab determined 
using 89Zr-Df-Bz-NCS-Ab binding to immobilized TEM-1 in the presence of increasing amounts of Df-Bz-NCS-Ab (conjugated) or Ab 
(unconjugated). Df-Bz-NCS-Ab IC
50
 = 13.1 nM, Ab IC
50
 = 14.5 nM. Assay performed as described in the Methods section.
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PET/CT imaging; after sacrifice, the organs of interest 
were harvested, weighed, and radioactivity measured and 
reported as the percent of injected dose/gram of tissue. 
This confirmed high radiopharmaceutical uptake in RD-
ES non-blocked xenograft relative to normal organs 
(Figure 5 and Supplemental Table 1). The ratio of tumor 
to muscle uptake was 21.9 in the RD-ED TEM-1+ cell line 
which was reduced to 3.59 upon blocking, comparable to 
the TEM-1 low expressing cell line LUPI at 4.3. 
dIscussIon
Sarcomas are an extremely heterogeneous group of 
tumors comprising over 50 subtypes that are associated 
with distinctive clinical profiles, response to individual 
therapies, and prognosis[30]. The reliable identification of 
TEM-1 in sarcoma may aid in the selection of patients for 
clinical trials that have the highest potential to benefit from 
such a targeted therapeutic strategy [5, 6, 19]. However, at 
Figure 4: In vivo Pet Imaging / radiopharmaceutical tumor uptake. A. Maximum intensity projections (MIP) of PET/CT 
images at 72 hours post-injection of 100 µCi (50 µg) 89Zr-Df-Bz-NCS-Ab. Signal intensity adjusted to equal scale. All data are presented as 
mean +/- standard deviation. b. Standard uptake values (SUV) obtained from PET/CT image analyses performed at three and seven days 
post injection. Day 3: RD-ES = 7 for block (b) and non-block (n/b), LUPI = 3. The same n for day 7.
table 1.
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this time, the ability to determine the clinically relevant 
expression of TEM-1 in patients with metastatic disease 
relies on biopsies of single lesions of primary tumors 
which may not represent the overall TEM-1 expression 
in a patient. The use of immunoPET in the imaging of 
malignancies has increased in use recently, benefiting from 
advances in PET/CT technology, radionuclide chemistry, 
and use of improved chelates for radiometal chemistry[4, 
5, 7, 25, 31, 32]
We have used FACS analysis and 
immunofluorescence to identify high and null TEM-1 
expressing sarcoma cell lines, and have identified two high 
expressing cell lines. RD-ES, a Ewing’s sarcoma line, and 
FUJI, a synovial sarcoma line, showed strong binding of 
the humanized TEM-1 antibody, Ontuxizumab, via FACS 
analysis and immunofluorescence, with confirmation 
via Western blotting. Paired cell lines, LUPI (Ewing’s 
sarcoma) and SYO-1 (synovial sarcoma), were identified 
as null and low expressers of TEM-1, respectively, as were 
the remainder of the 13 sarcoma cell lines screened in this 
fashion. Ontuxizumab was successfully conjugated to 
DFO and labeled with 89Zr without altering the antibody’s 
immunoreactivity. It displayed strong affinity to both 
high-expressing cell lines, RD-ES and FUJI in vitro. The 
in vivo utility of 89Zr-Ontuxizumab was demonstrated 
in RD-ES and LUPI xenografts with RD-ES xenografts 
displaying significantly higher SUVs at post-injection 
PET imaging at both 3 and 7 days when compared to 
LUPI xenografts. Blocking of the radiolabeled antibody 
at both 3 and 7 days post-injection with unconjugated 
Ontuxizumab demonstrated high specificity of the 
radiolabeled antibody for the TEM-1 expressing RD-ES 
xenografts. Biodistribution studies performed 7 days post-
injection of the 89Zr-Ontuxizumab showed accumulation 
of the antibody within the target tumor, while non-target 
tissues and organs of interest showed very little uptake of 
the antibody. 
The sequential process of screening cell lines for 
a specific monoclonal antibody with subsequent in vivo 
demonstration of 89Zr-labeled monoclonal antibody proves 
the utility of this in vivo TEM-1 expression PET test for 
human clinical screening applications. The findings in 
this paper await formal clinical trial testing in humans to 
demonstrate the utility of using radiolabeled Ontuxizumab 
as the target of the antibody, endosialin, is also expressed 
on blood vessels. In addition, the pharmacokinetics of the 
antibody’s clearance may be very different in humans than 
mice, but this awaits formal testing in humans. Clinically, 
reliable PET imaging of anti-TEM-1 antibody in patients 
with sarcoma may allow for stratification of patients into 
cohorts that will attain the greatest benefit from anti-
TEM-1 therapy. 
Figure 5: biodistribution. Post PET (Day 7) biodistribution of 89Zr-Df-Bz-NCS-Ab for mice bearing RD-ES (N = 4) and LUPI (N = 3) 
xenografts. Data is presented as % ID/g.  Blocked animals (N = 4) were pre-administered with 1 mg of native antibody to confirm specificity 




All experiments involving the use of radioactive 
materials at Washington University are conducted under 
the authorization of the Radiation Safety Committee in 
accordance with the University’s Nuclear Regulatory 
Commission license. Activity was determined with a 
Capintec CRC-25 Dose Calibrator calibrated to a factor of 
465 for 89Zr (Capintec, Ramsey, NJ). All chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise specified, and all solutions were prepared using 
ultrapure water with an 18 MΩ-cm resistivity produced by 
a Millipore Integral 5 water purification system (Millipore, 
Billerica, MA). 
cell lines and antibodies
Cell lines were purchased from ATCC, unless 
otherwise specified.  SYO-1 and FUJI were kindly 
provided by Dr. Akira Kawai (National Cancer Centre 
Hospital, Tokyo, Japan) and Dr. Kazuo Nagashima 
(Hokkaido University School of Medicine, Sapporo, 
Japan) and LUPI was a gift from Dr. John Pfeiffer 
(Washington University in St. Louis). All complete 
media was supplemented with 10% FBS and Penicillin-
Streptomycin 100x (10,000 U/mL) (Life Technologies, 
Grand Island, NY). LUPI, RD-ES, SK-ES, FUJI and 
RD lines were cultured in RPMI Medium 1640 (Life 
Technologies, Grand Island, NY), SYO-1, ST-88 were 
maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies, Grand Island, NY), SK-
LMS-1, SK-UT-1, MG63, MNNG/HOS, HT-1080 were 
cultured in Modified Eagle’s Medium (MEM) (Life 
Technologies, Grand Island, NY), and U2-OS was 
maintained in McCoy’s Medium (Life Technologies, 
Grand Island, NY). All cell lines other than LUPI, SYO-
1 and FUJI are from ATCC and cultured less than six 
months. The SYO-1 and FUJI cell lines were authenticated 
by confirming the expression of the pathognomic SYT-
SSX fusion gene by RT-PCR and LUPO was authenticated 
by confirming the expression of the pathognomic 
EWS-Fli1 fusion gene by RT-PCR. All cell lines were 
determined to be mycoplasma free using the LookOut 
Mycoplasma PCR Detection kit. (Sigma-Aldrich, St. 
Louis, MO).
For cell plating involved in fluorescence-activated 
cell sorting (FACS) analysis, cells were passaged and 
plated using 2.5mL of Enzyme-Free Cell Dissociation 
Buffer (EFCD) (Life Technologies Cat# 13150-016). 
Anti-TEM-1 antibody (MORAb-004; Ontuxizumab) was 
provided by Morphotek, Inc. at a stock concentration of 
5mg/mL and stored at 4°C. Anti-TEM-1 antibody (1D2.
H12.E7.G9) was also provided by Morphotek. Purified 
TEM-1 antigen was provided by Morphotek, Inc. and 
stored at -20°C. HRP-Goat anti-Rat IgG + IgM was from 
Jackson ImmunoResearch (West Grove, PA Cat# 112-035-
068), and anti-human beta-actin was from Sigma Aldrich 
(Cat# A1978). Anti-human IgG-FITC was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, Cat # sc-
2456).
Fluorescence-activated cell sorting and analysis
For the evaluation of TEM-1 expression by FACS, 
cell lines were plated in a 6-well format at 4x105 cells per 
well in triplicate. At 24 hours, media was removed from 
each well and collected into a labeled flow cytometry 
tube. Each well was washed with 1X phosphate buffered 
saline (PBS) (Life Technologies, Grand Island, NY) and 
washings collected. Cells were treated with EFCD for 5-7 
minutes (min) at 37°C. Cells were resuspended in PBS 
and collected and centrifuged at 400g for 5 min and then 
resuspended in a stock solution of 2% FBS and 2mM 
EDTA in PBS (stock solution A). Primary labeling with 
a 1:100 dilution of Ontuxizumab at 4°C for 30 min was 
performed. After incubation, samples were centrifuged at 
400g for 5 min, resuspended and washed with 1X PBS. 
Secondary labeling was performed with 1:50 dilution of 
FITC-labeled goat anti-human secondary antibody for 
20-30 min at 4°C. After incubation, all samples were 
centrifuged at 400g for 5 min and washed with PBS. 
Finally, cell pellets were resuspended in 1%BSA + 2mM 
EDTA + 1% sodium azide in 1X PBS. The antibody-free 
unstained sample was provided for each cell line to allow 
for proper gating and samples without primary antibody 
labeling were also used to determine background. The 
cell line (RD-ES) was used as a positive control in all 
experiments. FACS analysis was performed with a Becton 
Dickinson FACScan (BD Instruments, San Jose, CA) and 
FlowJo X (FlowJo, LLC, Ashland, OR). 
Western blot analysis
Four cell lines (RD-ES, LUPI, SYO-1, FUJI) were 
cultured, passaged, and dissociated utilizing media and 
agents described above. Cell were collected, placed on 
ice, and lysed with RIPA buffer over 40 min. Samples 
were then centrifuged for 15 min at 4°C. Lysates were 
transferred into a fresh tube with 4X LDS Loading Buffer 
(Life Technologies). Samples were boiled at 100oC for 
5 min, placed on ice, loaded on a NuPAGE 4-12% Bis-
Tris Gel 1.0 and run for 55 min at 170 Volts. Protein 
was transferred onto filters (Novex iBlot 2 PVDF Mini 
Stacks) via Novex iBlot2 Device (Life Technologies, 
Grand Island, New York) and blocked with 5% milk in 
1x 5% PBS-Tween for 2 hours at room temperature (RT). 
The primary antibody to TEM-1 (Rat-Anti human 16D2.
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H12.E7.G9) at a concentration of 1µg/mL was added and 
incubated overnight at 4°C. Filters were washed three 
times in 1X PBS-Tween at RT for 15 min 5% PBS-Tween 
was added to each blot along with HRP-Goat Anti-Rat IgG 
at a concentration of 1:10,000 and incubated for 1 hour at 
RT. Filters were washed 3 times in 1X PBS-Tween for 15 
min at RT. SuperSignal WestFemto Maximum Sensitivity 
Substrate Kit (ThermoScientific, Waltham, MA) was used 
to prepare Femto Streptavidin 1:1 solution and applied 
to filters. Images were captured via Omega Ultra-Lum 
(Ultralum Inc.; Part #: 910-1024-12; Model: Omega 12iC; 
Serial#: 6502) and analyzed for TEM-1 expression. 
Semi-quantitative immunofluorescence
All cell lines were plated at 5x104 cells/well onto 
an 8-chamber slide. At two days after plating, the media 
was removed from the wells and the slides were incubated 
in a 4% paraformaldehyde for 10 min at RT. Slides were 
washed with 1X PBS three times, then incubated in a 
1X PBS and 50% goat serum for 30 min at 37°C. Slides 
were incubated for one hour at 37°C in a 1:100 dilution 
of primary antibody (Ontuxizumab) diluted in 1X PBS 
and 50% goat serum. Slides were washed in 1X PBS 3 
times and then incubated in a 1:100 dilution of FITC-
labeled goat anti-human secondary antibody (sc-2456, 
Santa Cruz Biotech) for 1 hour at 37°C. Slides were 
washed in 1X PBS 3 times, and mounted in Dapi/Antifade 
solution (SlowFade Gold antifade reagent with DAPI). 
Images were taken with a locked exposure time of 25 
milliseconds using a 60x objective for FITC to allow for 
semi-quantitative microscopy across all images.
Animal models
Nude athymic mice (Nu/J homozygous, 
Cat#002019, The Jackson Lab) were xenografted with 
1x106 RD-ES or LUPI cells that had been resuspended 
in 1X PBS 30% Matrigel (Corning, Inc., Cat # CB-
40234). Mice were anesthetized with 1-2% isofluorane 
and injected at the left shoulder for RD-ES xenografts and 
injected at the right shoulder for LUPI xenografts. Mice 
were observed until tumor size was 100mm3 and then 
underwent small animal PET/CT imaging. 
89Zr production and purification
89Zr was produced via the 89Y(p,n)89Zr reaction using 
the CS-15 cyclotron (Cyclotron Corporation, Berkeley, 
CA) and separated via ion exchange chromatography 
using an in-house automated system as previously 
described [22-24], with a resulting specific-activity of 22-
134 mCi/μmole. 
radiolabeling of anti-teM-1 antibody
89Zr labeling was performed according to previously 
published methods [25, 26]. Briefly, Ontuxizumab 
(5 mg/ml) was conjugated to isothiocyanatobenzyl-
desferrioxamine-NCS (Df-Bz-NCS) (Macrocyclics, 
Dallas, TX) at 1:10 (Antibody) Ab to chelate ratio for 1 
hour at 37°C in the presence of 0.1 M sodium carbonate 
buffer (pH 9). The unreacted chelate was removed 
utilizing Zeba desalting columns (40,000 MW cut off, 
0.5 mL volume, ThermoFisher Scientific, Rockford, 
IL). The Ab-Df-Bz-NCS conjugate was combined 
with 89Zr oxalate at 1:1 or 1:5 mg/mCi and pH 7.1. 
The mixture was incubated for one hour at 37°C. The 
labeling efficiency was confirmed by radio-iTLC on glass 
microfiber chromatography paper impregnated with silica 
gel (Agilent Technologies, Lake Forest, CA) with 50 
mM diethylene triamine pentaacetic acid (DTPA) eluent 
solvent and a Bioscan AR- 2000 radio-TLC scanner 
equipped with a 10% methane/argon gas supply. The 
specific activity obtained was 1-5 µCi/µg with labeling 
efficiency of 98-100%; therefore, the compounds were 
used with no further purification.
In vitro cell binding
Cells were grown to ~50% confluence in 6-well 
tissue culture plates and incubated with 1-2 µCi (0.5 µg) 
of radiolabeled Ontuxizumab in 500 µL of complete media 
for 35 min at 37°C. Unbound antibody was removed by 
washing cells thrice with PBS. Cells were then solubilized 
in PBS containing 0.1% SDS, the lysate was transferred 
to microfuge tubes and cell associated activity detected 
with a gamma-counter. Extra wells with untreated cells 
corresponding to each cell line were assessed for cell 
number and used as reference. The results were expressed 
as counts per min per 5 x105 cells (CPM/5x105 cells). 
Internalization assay
Cells were plated in 24-well tissue culture plates 
at 1x105 cells/well and incubated with 1-2 µCi (0.5 µg) 
of radiolabeled antibody in 250 µl of complete media 
per well for 0.5, 1, 2, 4, 6, and 24 hours in humidified 
atmosphere supplemented with 5% CO2 at 37°C. Unbound 
antibody was removed by washing cells three times with 
PBS. Cells were then harvested by incubating in 250 µl 
of 0.05% Trypsin-EDTA (Thermo Fisher) for 5 minutes 
at 37°C. Cells were pelleted, the supernatant collected, 
and the pellet re-suspended in 250 µl of 20 mM sodium 
citrate/150 mM sodium chloride, pH 2.5 for 2 minutes at 
22°C to remove the membrane associated antibody. Cells 
were pelleted, the supernatant collected and combined with 
the Trypsin supernatant to represent the membrane bound 
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antibody. The cell pellet was washed once with PBS. The 
activity associated with the internalized (cell pellet) and 
membrane bound (supernatants) was determined with a 
gamma-counter. 
In vivo biodistribution
Biodistribution studies were conducted immediately 
after 7 days post injection PET/CT imaging studies. 
Briefly, 100 µCi (50 ug) 89Zr-Df-Bz-NCS-Ab were tail 
vein injected. Animals were sacrificed, organs of interest 
were harvested, weighed, and associated radioactivity 
determined on a γ-counter. After correcting for background 
and decay, the percent-injected dose per gram (%ID/gram) 
and percent-injected dose per organ (%ID/organ) were 
calculated by comparison to a weighed, counted standard. 
small animal Pet/ct imaging
Prior to imaging, mice were injected intravenously 
(tail vein) with 100 µCi of 89Zr-Df-Bz-NCS-Ab. At three 
and seven days post-injection mice were anaesthetized 
with 1%-2% isoflurane and imaged with an Inveon small 
animal PET/CT scanner (Siemens Medical Solutions). 
Static images were collected for 20 min and reconstructed 
with the Maximum A Posteriory (MAP) probability 
algorithm [27] followed by co-registration with the Inveon 
Research Workplace 4.0 (IRW) image display software 
(Siemens Medical Solutions, Knoxville, TN). Regions 
of interest (ROI) were selected from PET images using 
CT anatomical guidelines and the activity determined 
with IRW software. Standard uptake values (SUV) were 
determined as nCi/cc x animal weight/ injected dose. To 
block the binding of 89Zr labeled antibody, 40 mg/kg of 
unlabeled antibody was injected intravenously (tail vein) 
10 minutes prior to the labeled antibody.
statistical analysis
Data are expressed as mean ± standard deviation 
(SD) unless noted otherwise. Statistical significance was 
determined using the unpaired, 2-tailed Student t-test 
and 95% confidence level. P values less than 0.05 were 
considered significant. All data were analyzed and plotted 
using GraphPad Prizm version 5.0 or MEDCalc.
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